Paradigm Biopharmaceuticals Limited

Research Paradigm Biopharmaceuticals Limited (P86) on Bullrun: market cap EUR 54.85M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerP86
• ExchangeF
• CountryAustralia
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Market capEUR 54.85M
• Financial periodFY2024
• RevenueEUR 65.80K
• Revenue growth40.7%
• Net income-EUR 58.65M
• Free cash flow-EUR 65.94M
• Gross margin86.3%

Valuation Snapshot

latest market cap is EUR 54.85M.

About Paradigm Biopharmaceuticals Limited

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.

Frequently asked questions

What is Paradigm Biopharmaceuticals Limited's market cap?

Paradigm Biopharmaceuticals Limited's market capitalization is EUR 54.85M.

What does Paradigm Biopharmaceuticals Limited do?

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia.